Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.81 |
| ▸ | NPC1 | O15118 | 8/20 | 0.81 |
| ▸ | RAB9A | P51151 | 8/20 | 0.81 |
| ▸ | PKM | P14618 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | VCP | P55072 | 1/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.63 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23539303 | 0.91 | MEN1 (0.81) | MEN1KMT2ANPC1RAB9APKM | |
| SCHEMBL208751 | 0.89 | MEN1 (0.78) | MEN1KMT2ANPC1RAB9APKM | |
| SCHEMBL23539674 | 0.88 | MEN1 (0.80) | MEN1KMT2ANPC1RAB9APKM | |
| SCHEMBL7540052 | 0.88 | MAPK1 (0.84) | MEN1KMT2ANPC1RAB9APKM | |
| SCHEMBL208199 | 0.87 | RAB9A (0.82) | MEN1KMT2ANPC1RAB9APKM | |
| Bromide SCHEMBL7691671 | 0.86 | MAPK1 (0.82) | MEN1KMT2ANPC1RAB9APKM | |
| SCHEMBL208010 | 0.84 | MEN1 (0.74) | MEN1KMT2ANPC1RAB9APKM | |
| SCHEMBL1889546 | 0.83 | MEN1 (0.76) | MEN1KMT2ANPC1RAB9APKM | |
| SCHEMBL4834856 | 0.82 | GAA (0.72) | MEN1KMT2ANPC1RAB9APKM | |
| SCHEMBL22560267 | 0.82 | MAPK1 (1.00) | MEN1KMT2ANPC1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | PRISM MEDICINES, INC. | 2025-01-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11608329-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20210230153-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210230153-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127301-A1 | 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS | Ikena Oncology, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127301-A1 | 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS | Ikena Oncology, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | MEN1 4851/4885KMT2A 1031/4885NPC1 1552/4885 |
| US-11608329-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | MEN1 4851/4885KMT2A 1031/4885NPC1 1552/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | MEN1 4851/4885KMT2A 1031/4885NPC1 1552/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | MEN1 4851/4885KMT2A 1031/4885NPC1 1552/4885 |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | MEN1 3862/4885KMT2A 3476/4885NPC1 62/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | MEN1 3862/4885KMT2A 3476/4885NPC1 62/4885 |
| US-20210230153-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | MEN1 4851/4885KMT2A 1031/4885NPC1 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.